Monopar Therapeutics Inc. (MNPR)

Market Cap	34.56M
Revenue (ttm)	n/a
Net Income (ttm)	-10.30M
Shares Out	12.92M
EPS (ttm)	-0.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,350
Open	2.56
Previous Close	2.69
Day's Range	2.56 - 2.82
52-Week Range	1.39 - 4.88
Beta	1.11
Analysts	Buy
Price Target	18.02 (+548.2%)
Earnings Date	Mar 23, 2023

About MNPR

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 19, 2019
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: MNPR

Analyst Forecast

According to 12 analysts, the average rating for MNPR stock is "Buy." The 12-month stock price forecast is $18.02, which is an increase of 548.20% from the latest price.

Price Target

$18.02

(548.20% upside)

Analyst Consensus: Buy